Literature DB >> 35999480

Recent Advances and Therapeutic Strategies Using CRISPR Genome Editing Technique for the Treatment of Cancer.

Shreyasi Maity1, Rishyani Mukherjee1, Satarupa Banerjee2.   

Abstract

CRISPR genome editing technique has the potential to target cancer cells in a precise manner. The latest advancements have helped to address one of the prominent concerns about this strategy which is the off-target integrations observed with dsDNA and have resulted in more studies being carried out for potentially safer and more targeted gene therapy, so as to make it available for the clinical trials in order to effectively treat cancer. CRISPR screens offer great potential for the high throughput investigation of the gene functionality in various tumors. It extends its capability to identify the tumor growth essential genes, therapeutic resistant genes, and immunotherapeutic responses. CRISPR screens are mostly performed in in vitro models, but latest advancements focus on developing in vivo models to view cancer progression in animal models. It also allows the detection of factors responsible for tumorigenesis. In CRISPR screens key parameters are optimized in order to meet proficient gene targeting efficiencies. It also detects various molecular effectors required for gene regulation in different cancers, essential pathways which modulate cytotoxicity to immunotherapy in cancer cells, important genes which contribute to cancer cell survival in hypoxic states and modulate cancer long non-coding RNAs. The current review focuses on the recent developments in the therapeutic application of CRISPR technology for cancer therapy. Furthermore, the associated challenges and safety concerns along with the various strategies that can be implemented to overcome these drawbacks has been discussed.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CRISPR; CRISPR screen; Cancer; Gene targeting; Therapeutic; Tumorigenesis

Year:  2022        PMID: 35999480     DOI: 10.1007/s12033-022-00550-9

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.860


  117 in total

Review 1.  Transcription factor decoy: a pre-transcriptional approach for gene downregulation purpose in cancer.

Authors:  Seyed Mohammad Ali Hosseini Rad; Lida Langroudi; Fatemeh Kouhkan; Laleh Yazdani; Alireza Nouri Koupaee; Sara Asgharpour; Zahra Shojaei; Taravat Bamdad; Ehsan Arefian
Journal:  Tumour Biol       Date:  2015-04-04

2.  CRISPR provides acquired resistance against viruses in prokaryotes.

Authors:  Rodolphe Barrangou; Christophe Fremaux; Hélène Deveau; Melissa Richards; Patrick Boyaval; Sylvain Moineau; Dennis A Romero; Philippe Horvath
Journal:  Science       Date:  2007-03-23       Impact factor: 47.728

Review 3.  Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.

Authors:  Ling Li; Shuo Hu; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2018-04-18       Impact factor: 12.479

4.  Role of Oct4-Sox2 complex decoy oligodeoxynucleotides strategy on reverse epithelial to mesenchymal transition (EMT) induction in HT29-ShE encompassing enriched cancer stem-like cells.

Authors:  Zahra Bigdelou; Yousef Mortazavi; Zohreh Saltanatpour; Zoleykha Asadi; Mehdi Kadivar; Behrooz Johari
Journal:  Mol Biol Rep       Date:  2020-02-03       Impact factor: 2.316

Review 5.  An overview of applications of CRISPR-Cas technologies in biomedical engineering.

Authors:  Saleh Jamehdor; Kasra Arbabi Zaboli; Sina Naserian; Jose Thekkiniath; Honey Alef Omidy; Ali Teimoori; Behrooz Johari; Amir Hossein Taromchi; Yu Sasano; Saeed Kaboli
Journal:  Folia Histochem Cytobiol       Date:  2020-09-26       Impact factor: 1.698

6.  Suppressing the metastatic properties of the breast cancer cells using STAT3 decoy oligodeoxynucleotides: A promising approach for eradication of cancer cells by differentiation therapy.

Authors:  Mohammad Rahmati; Behrooz Johari; Mehdi Kadivar; Elham Rismani; Yousef Mortazavi
Journal:  J Cell Physiol       Date:  2020-01-08       Impact factor: 6.384

Review 7.  Interplay between Cell Death and Cell Proliferation Reveals New Strategies for Cancer Therapy.

Authors:  Luke V Loftus; Sarah R Amend; Kenneth J Pienta
Journal:  Int J Mol Sci       Date:  2022-04-25       Impact factor: 6.208

8.  Increasing the colon cancer cells sensitivity toward radiation therapy via application of Oct4-Sox2 complex decoy oligodeoxynucleotides.

Authors:  Behrooz Johari; Hamed Rezaeejam; Mohammad Moradi; Zahraa Taghipour; Zohreh Saltanatpour; Yousef Mortazavi; Leila Nasehi
Journal:  Mol Biol Rep       Date:  2020-08-31       Impact factor: 2.316

9.  Multiplex genome engineering using CRISPR/Cas systems.

Authors:  Le Cong; F Ann Ran; David Cox; Shuailiang Lin; Robert Barretto; Naomi Habib; Patrick D Hsu; Xuebing Wu; Wenyan Jiang; Luciano A Marraffini; Feng Zhang
Journal:  Science       Date:  2013-01-03       Impact factor: 47.728

10.  Virus-like nanoparticle as a co-delivery system to enhance efficacy of CRISPR/Cas9-based cancer immunotherapy.

Authors:  Qi Liu; Chun Wang; Yadan Zheng; Yu Zhao; Ying Wang; Jialei Hao; Xinzhi Zhao; Kaikai Yi; Linqi Shi; Chunsheng Kang; Yang Liu
Journal:  Biomaterials       Date:  2020-08-07       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.